<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        12-313-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LIVAZO 4 mg film-coated tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PITAVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Algorithm SAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Livazo contains a medicine called pitavastatin. This belongs to a group of medicines called &lsquo;statins&rsquo;. Livazo is used to correct the levels of fat (lipid: cholesterol and triglycerides) in your blood and can be taken by children from the age of 6 years, as well as by adults. An imbalance of fats particularly cholesterol can sometimes lead to a heart attack or stroke.</p><p>You have been given Livazo because you have an imbalance of fats and changing your diet and making lifestyle changes have not been enough to correct this. You should continue with your cholesterol-lowering diet and lifestyle changes while you are taking Livazo.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Livazo if:</p><p>&bull; you are allergic (hypersensitive) to pitavastatin, any other statin or the other ingredients of Livazo (listed in &ldquo;6. Further</p><p>information&rdquo;).</p><p>&bull; you are&nbsp; breast-feeding.</p><p>&bull; you currently have liver problems.</p><p>&bull; you take ciclosporin &ndash; used after an organ transplant.</p><p>&bull; you have repeated or unexplained muscle aches or pains.</p><p>If you are not sure, talk to your doctor or pharmacist before</p><p>taking Livazo.</p><p>&nbsp;</p><p>&nbsp;</p><p>Take special care with Livazo</p><p>Check with your doctor or pharmacist before taking your</p><p>medicine if:</p><p>&bull; you have severe respiratory failure (severe breathing problems).</p><p>&bull; you have ever had problems with your kidneys.</p><p>&bull; you have previously had liver problems. &lsquo;Statins&rsquo; can affect the liver in a small number of people. Your doctor will</p><p>usually carry out a blood test (liver function test) before and during treatment with Livazo.</p><p>&bull; you have ever had problems with your thyroid gland.</p><p>&bull; you or any member of your family have a history of muscle problems.</p><p>&bull; you have had a previous history of muscle problems when</p><p>taking other cholesterol-lowering medicines (e.g. statins or fibrates).</p><p>&bull; you drink excessive amounts of alcohol.</p><p>&bull; you are taking or have taken in the last 7 days a medicine called fusidic acid (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and Livazo can lead to serious muscle problems (rhabdomyolysis).</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Livazo. Also tell your doctor or pharmacist if you have a muscle weakness that is constant. Additional tests and medicines may be</p><p>needed to diagnose and treat this.</p><p>&nbsp;</p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing</p><p>diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>&nbsp;</p><p>Children and Adolescents</p><p>Livazo should not be given to children aged below 6 years.</p><p>Taking other medicines with Livazo</p><p>Please tell your doctor or pharmacist if you are taking, or have recently taken, any other medicines. This includes any</p><p>medicines obtained without a prescription and herbal&nbsp;</p><p>remedies. Some medicines can stop each other from working</p><p>properly.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following:</p><p>&bull; other medicines called &lsquo;fibrates&rsquo; - such as gemfibrozil and fenofibrate.</p><p>&bull; erythromycin or rifampicin - types of antibiotics used for</p><p>infections.</p><p>&bull; warfarin or any other medicine used to thin the blood.</p><p>&bull; medicines for HIV called &lsquo;protease inhibitors&rsquo;&nbsp;(e.g. ritonavir, lopinavir, darunavir, atazanavir) and &lsquo;non-nucleoside reverse transcriptase inhibitors&rsquo; (e.g. efavirenz)</p><p>&bull; niacin (vitamin B3).</p><p>&bull; ciclosporin is contraindicated with pitavastatin</p><p>&bull; if you need to take oral fusidic acid to treat a bacterial</p><p>infection you will need to temporarily stop using this</p><p>medicine. Your doctor will tell you when it is safe to restart Livazo use. Taking Livazo with fusidic acid may rarely lead to muscle weakness, tenderness or pain&nbsp; (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4.</p><p>&bull; If you are taking medicines containing glecaprevir and pibrentasvir, medicines used to treat Hepatitis C. The doctor may need to change the dose of Livazo.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Livazo.</p><p>&nbsp;</p><p>Taking Livazo with food and drink</p><p>Livazo can be taken with or without food.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>Do not take Livazo if you are breast-feeding. Your doctor can help you determine whether it will be better for you to stop Livazo temporarily while breastfeeding or whether you need to continue taking it and so should not breastfeed.<br />If you become pregnant or suspect you are pregnant while taking Livazo, talk to your doctor.<br />Always consult with doctor about the use of all medicines during pregnancy or while breastfeeding. Your doctor will be able to advise whether you should stop taking Livazo during pregnancy and whether you may stop Livazo temporarily while breastfeeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Livazo is not expected to interfere with your ability to drive or operate machinery. However, if you feel dizzy or sleepy whilst taking Livazo, do not drive, use any machinery or tools.</p><p>&nbsp;</p><p>Important information about some of the ingredients of Livazo</p><p>Livazo contains lactose (a type of sugar). If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Livazo exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Taking this medicine</p><p>Swallow the tablet whole with water, with or without food. You can take it at any time of day. However, try to take your tablet at the same time every day.</p><p>&nbsp;</p><p>How much to take</p><p>&bull; The recommended dose is 2mg once a day. After a few weeks your doctor may decide to increase your dose. The maximum dose&nbsp;for adults and children over 10 years is 4mg each day.</p><p>&bull; If you have problems with your liver you should not take more than 2mg a day.</p><p>&nbsp;</p><p>Use in children and adolescents</p><p>&bull; The maximum dose in children under 10 years is 2 mg each day.</p><p>&bull; If necessary, the tablets may be dispersed in a glass of water immediately before taking, then rinse the glass with a second volume of water and again drink immediately. Do not use fruit juices or milk to disperse the tablets.</p><p>&bull; Livazo is not recommended for use in children aged below 6 years.</p><p>Other things you need to know whilst taking Livazo</p><p>&bull; If you go into hospital or receive treatment for another</p><p>problem, tell the medical staff that you are taking Livazo.</p><p>&bull; Your doctor may do regular cholesterol checks.</p><p>&bull; Do not stop taking Livazo without talking to your doctor first. Your cholesterol levels might increase.</p><p>&nbsp;</p><p>If you take more Livazo than you should</p><p>If you take more Livazo than you should, talk to a doctor or go to hospital straight away. Take the medicine pack with you.</p><p>&nbsp;</p><p>If you forget to take a dose</p><p>Do not worry, just take your next dose at the correct time. Do not take a double dose to make up for the one you have missed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Livazo can cause side effects, although not everybody will have them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p>Stop taking Livazo and see a doctor straight away, if you notice any of the following serious side effects - you may need urgent medical</p><p>treatment:</p><p>&bull; allergic reaction &ndash; the signs may include: difficulty</p><p>breathing, swelling of the face, lips, tongue or throat, problems swallowing, severe itching of the skin (with raised lumps).</p><p>&bull; unexplained muscle pain or weakness, especially if you feel unwell, have a fever or have reddish brown urine. Livazo can rarely (less than 1 in 1,000 people) cause unpleasant muscle effects. If not investigated they can lead to serious problems such as abnormal muscle breakdown (rhabdomyolysis), which can lead to kidney problems.</p><p>&bull; breathing problems including persistent cough and/or</p><p>shortness of breath or fever.</p><p>&bull; liver problems which may cause yellowing of the skin and eyes (jaundice)</p><p>&bull; pancreatitis (severe pain in the abdomen and back)</p><p>&nbsp;</p><p>Most other side effects are usually mild and disappear after a short time, these include:</p><p>&nbsp;</p><p>Common (affects less than 1 in 10 people)</p><p>&bull; joint pain, muscle ache</p><p>&bull; constipation, diarrhoea, indigestion, feeling sick</p><p>&bull; headache.</p><p>&nbsp;</p><p>Uncommon (affects less than 1 in 100 people)</p><p>&bull; muscle spasms</p><p>&bull; feeling weak, weary or unwell</p><p>&bull; swelling of the ankles, feet or fingers</p><p>&bull; stomach pain, dry mouth, being sick, loss of appetite, altered taste</p><p>&bull; pale skin and feeling weak or breathless (anaemia)</p><p>&bull; itching or rash</p><p>&bull; ringing in the ears</p><p>&bull; feeling dizzy or sleepy, insomnia (other sleep disturbances including nightmares)</p><p>&bull; increased need to go to the toilet (urinary frequency)</p><p>&bull; feeling of numbness and reduced sensation in the fingers, toes, legs and face.</p><p>&nbsp;</p><p>Rare (affects less than 1 in 1,000 people)</p><p>&bull; liver problems</p><p>&bull; pancreatitis</p><p>&bull; redness of the skin, raised red itchy skin</p><p>&bull; deteriorating eye sight</p><p>&bull; pain in the tongue</p><p>&bull; unpleasant sensation in the abdomen</p><p>&bull;Breast enlargement in men (gynaecomastia).</p><p>&nbsp;</p><p>Side effects of unknown frequency</p><p>&bull; muscle weakness that is constant</p><p>&bull; lupus-like syndrome (including rash, joint disorders and effects on blood cells)</p><p>&nbsp;</p><p>Other possible side effects</p><p>&bull; memory loss</p><p>&bull; sexual difficulties</p><p>&bull; depression</p><p>&bull; diabetes. This is more likely if you have high levels of</p><p>sugars and fats in your blood, if you are overweight and have high blood pressure. Your doctor may monitor you while you are taking this medicine.</p><p>&nbsp;</p><p>If any of the side effects become troublesome, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>To report any side effect<br />Lebanon and all MENA countries<br />Algorithm SAL<br />Fax: +961-9-222141<br />E-mail: pharmacovigilance@algorithm-lb.com<br />Website: www.algorithm-lb.com<br />Saudi Arabia<br />Also contact:<br />The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />Also contact the relevant competent authorit</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>To protect from light keep the blisters in the carton.</p><p>Do not use Livazo after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of that month. Medicines should not be disposed of via</p><p>wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pitavastatin.</p><p>Each tablet contains 2.09 mg or 4.18 mg of pitavastatin</p><p>calcium equivalent to 2 mg or 4 mg respectively of free base.</p><p>The other ingredients are: Lactose monohydrate, low</p><p>substituted hydroxypropylcellulose, hypromellose (E464),</p><p>magnesium aluminometasilicate, magnesium stearate,</p><p>titanium dioxide (E171), triethyl citrate (E1505) and colloidal anhydrous silica.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Livazo tablets are round, white, biconvex film coated tablets engraved “ALG” on one side and “L2” or “L4” on the other. 
Livazo is available in packs of 7, 28, 30 or 100 tablets. 

Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization&nbsp; Holder And Final Batch Releaser:</p><p>ALGORITHM S.A.L. Zouk Mosbeh, Lebanon</p><p>&nbsp;</p><p>Manufacturer:</p><p>ALGORITHM S.A.L. Zouk Mosbeh, Lebanon</p><p>&nbsp;</p><p>Under license from</p><p>Kowa Pharmaceutical Europe Co. Ltd., UK.</p><p>&reg; Registered Trademark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rev No. 04/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي ليفازو<strong><sup>م</sup></strong> على دواء يُسمّى بيتافاستاتين، ينتمي إلى مجموعة من الأدوية تُسمّى أدوية &laquo;الستاتين&raquo;. يُستعمل ليفازو<strong><sup>م</sup></strong> لتصحيح مستويات الدهن (الشحم: الكولسترول وثلاثي الغليسيريد) في الدم ويمكن أن يأخذه الأطفال ابتداء من عمر الست سنوات والبالغون أيضًا. يمكن أن يسبّب أحيانًا اختلال في الدهون لا سيّما الكولسترول نوبة قلبيّة أو سكتة دماغيّة.&nbsp;</p><p dir="RTL">لقد وُصف ليفازو<strong><sup>م</sup></strong> لك لأنّك تعاني من اختلال في توازن الدهون ولم يكن تغيير نظامك الغذائي ونمط عيشك كافيًا لتصحيح هذا الاختلال. يجب عليك مواصلة نظامك الغذائي المخفّض للكولسترول وتغيير نمط عيشك في خلال فترة استعمالك ليفازو<strong><sup>م</sup></strong>.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تأخذ ليفازو<strong><sup>م</sup></strong> إذا:</p><p dir="RTL">&bull; كنت حسّاسًا (مصابًا بفرط حساسيّة) ضدّ البيتافاستاتين أو أيّ دواء آخر من أدوية الستاتين أو ضدّ المركّبات الأخرى في ليفازو<strong><sup>م</sup></strong> (المذكورة في القسم&nbsp; &laquo;6. معلومات إضافيّة&raquo;).&nbsp;</p><p dir="RTL">&bull; كنتِ&nbsp; مرضعة.&nbsp;</p><p dir="RTL">&bull; كنت تعاني حاليًا من مشاكل في الكبد.&nbsp;</p><p dir="RTL">&bull; كنت تأخذ السيكلوسبورين &ndash; الذي يُستعمل بعد غرس الأعضاء.&nbsp;</p><p dir="RTL">&bull; كنت تعاني من أوجاع أو آلام متكررة وغير مبرّرة في العضلات.&nbsp;</p><p dir="RTL">إذا لم تكن متأكّدًا، تحدّث إلى الطبيب أو الصيدلي قبل أخذ ليفازو<strong><sup>م</sup></strong>.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إعتمد عناية خاصة مع ليفازو<strong><sup>م</sup></strong>&nbsp;</p><p dir="RTL">تحقّق من طبيبك أو من الصيدلي قبل أخذ هذا الدواء إذا:</p><p dir="RTL">&bull; كان لديك فشل تنفسي حاد (مشاكل تنفسية شديدة).&nbsp;</p><p dir="RTL">&bull; عانيت يومًا من مشاكل كلويّة.&nbsp;</p><p dir="RTL">&bull; عانيت سابقًا من مشاكل في الكبد. يمكن أن تؤثّر أدوية &laquo;الستاتين&raquo; على الكبد لدى عدد محدود من الأشخاص. سوف يُجري لك طبيبك فحص دم (فحص وظيفة الكبد) قبل العلاج بليفازو<strong><sup>م</sup></strong> وبعده.&nbsp;</p><p dir="RTL">&bull; عانيت يومًا من مشاكل في غدّتك الدرقيّة.&nbsp;</p><p dir="RTL">&bull; عانيت سابقًا أنت أو أحد أفراد أسرتك من مشاكل عضليّة.&nbsp;</p><p dir="RTL">&bull; عانيت سابقًا من مشاكل عضليّة عند أخذ أدوية أخرى تخفّض الكولسترول (مثلاً أدوية الستاتين أو الفبرات).&nbsp;</p><p dir="RTL">&bull; كنت تشرب بإفراط كميّات من الكحول.&nbsp;</p><p dir="RTL">&bull; إذا كنت تأخذ أو أخذت في الأيّام السبعة الماضية دواء يُسمّى حمض الفوسيديك (دواء يُستعمل لحالات العدوى البكتيريّة) عن طريق الفم أو الحقن. فأخذ حمض الفوسيديك بالتزامن مع ليفازو<strong><sup>م</sup></strong> يمكن أن يؤدّي إلى مشاكل عضليّة خطيرة (انحلال الربيدات).</p><p dir="RTL">في حال كانت إحدى الحالات أعلاه تنطبق عليك (أو لم تكن متأكّدًا من ذلك)، تحدّث إلى الطبيب أو الصيدلي قبل أخذ ليفازو<strong><sup>م</sup></strong>. أعلم أيضًا طبيبك أو الصيدليّ الخاص بك إذا كنت تعاني من ضعف عضلي مستمرّ. قد يكون من الضروريّ إجراء فحوصات إضافيّة وأخذ أدوية إضافيّة لتشخيص هذه الحالة وعلاجها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في فترة أخذك هذا الدواء، سوف يراقبك طبيبك عن كثب إذا كنت مصابًا بداء السكري أو كنت تواجه خطر الإصابة به. يُحتمل أن تُصاب بداء السكّري إذا كانت مستويات السكّر والدهون في دمك مرتفعة أو إذا كنت تعاني من السمنة ومن ارتفاع ضغط الدم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا ينبغي إعطاء ليفازو<strong><sup>م</sup></strong> إلى الأطفال ما دون السادسة من العمر.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;أخذ أدوية أخرى مع ليفازو<strong><sup>م</sup></strong></p><p dir="RTL">الرجاء أن تُعلم الطبيب أو الصيدلي إذا كنت تأخذ حاليًا أو أخذت مؤخّرًا أيّ أدوية أخرى بما فيها تلك التي حصلت عليها من دون وصفة طبيّة والأدوية العشبيّة. فثمّة أدوية يمكن أن تؤثّر على فعاليّة بعضها البعض.&nbsp;</p><p dir="RTL">بصورة خاصة أعلم الطبيب أو الصيدلي إذا كنت تأخذ أيًّا من الأدوية التالية:</p><p dir="RTL">&bull; أدوية أخرى تُسمّى &laquo;فبرات&raquo; &ndash; مثل جمفيبروزيل وفينوفبرات.&nbsp;</p><p dir="RTL">&bull; إيريثرومايسين أو الريفامبيسين &ndash; أنواع من المضادات الحيويّة تُستعمل لعلاج الالتهابات.&nbsp;</p><p dir="RTL">&bull; الوارفارين أو أيّ دواء آخر يُستعمل لترقيق الدم.&nbsp;</p><p dir="RTL">&bull; أدوية السيدا المسمّاة &laquo;مثبّطات البروتياز&raquo; (مثل ريتونافير ، لوبينافير ، دارونافير ، أتازانافير) و &laquo;مثبطات النسخ العكسي غير النوكليوزيدية&raquo; (مثل إيفافيرينز)</p><p dir="RTL">&bull; نياسين (فيتامين ب3).</p><p dir="RTL">&bull; يمنع أخذ&nbsp; السيكلوسبورين بالتّزامن مع البيتافاستاتين.</p><p dir="RTL">&bull; إذا كنت تحتاج إلى أخذ حمض الفوسيديك لعلاج حالة عدوى بكتيريّة، سوف تحتاج إلى التوقّف مؤقتًا عن استعمال هذا الدواء. سوف يقول لك طبيبك متى يكون من الآمن أن تستأنف استعمال ليفازو. نادرًا ما قد يؤدي أخذ ليفازو مع حمض الفوسيديك إلى ضعف عضليّ أو إلى إيلام بالضغط أو إلى ألم (انحلال الربيدات). للمزيد من المعلومات حول انحلال الربيدات راجع القسم 4.</p><p dir="RTL">&bull; إذا كنت تتناول أدوية تحتوي على جليكابريفير وبيبرنتاسفير ، أدوية تستخدم لعلاج التهاب الكبد سي. قد يحتاج الطبيب إلى تغيير جرعة ليفازو<strong><sup>م</sup></strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال كانت إحدى الحالات أعلاه تنطبق عليك (أو لم تكن متأكّدًا من ذلك)، تحدّث إلى الطبيب أو الصيدلي قبل أخذ ليفازو<strong><sup>م</sup></strong>.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخذ ليفازو</strong><strong><sup>م</sup></strong><strong> مع الطعام والشراب</strong></p><p dir="RTL">يمكن أخذ ليفازو<strong><sup>م</sup></strong> مع الطعام أو بدونه.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">ا<strong>لحمل ، الإرضاع والخصوبة</strong></p><p dir="RTL">لا تأخذي ليفازو<strong><sup>م</sup></strong> إذا كنتِ مرضعة. يمكن لطبيبك مساعدتك في تحديد ما إذا كان من الأفضل لك التوقف عن تناول ليفازو<strong><sup>م</sup></strong> مؤقتًا أثناء الرضاعة الطبيعية أو ما إذا كنت بحاجة إلى الاستمرار في تناوله وبالتالي لا ينبغي عليك الإرضاع.</p><p dir="RTL">إذا أصبحت حاملاً أو تشتبهين في أنك حامل أثناء تناول ليفازو<strong><sup>م</sup></strong> ، تحدّثي إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري طبيبك دائمًا حول استخدام جميع الأدوية أثناء الحمل أو أثناء الرضاعة الطبيعية. سيكون طبيبك قادرًا على تقديم النصيحة فيما إذا كان عليك التوقف عن تناول ليفازو<strong><sup>م</sup></strong> أثناء الحمل وما إذا كان بإمكانك التوقف عن تناول ليفازو<strong><sup>م</sup></strong> مؤقتًا أثناء الرضاعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيّارات واستعمال الآلات</strong></p><p dir="RTL">لا يُتوقّع أن يؤثّر ليفازو<strong><sup>م</sup></strong> على قدرتك على القيادة أو تشغيل الآلات. ولكن إذا شعرت بالدوار أو بالنعاس في خلال فترة علاجك بليفازو<strong><sup>م</sup></strong>، لا تقد سيّارة ولا تستعمل أيّ آلة أو أدوات.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">معلومات مهمّة حول بعض مركّبات ليفازو<strong><sup>م</sup></strong></p><p dir="RTL">يحتوي ليفازو<strong><sup>م</sup></strong> على اللاكتوز (نوع من السكّر). إذا قال لك طبيبك إنّك لا تتحمّل بعض أنواع السكّر أو لا تهضمها، تحدّث إلى طبيبك قبل أخذ هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">خذ دائمًا ليفازو<strong><sup>م</sup></strong> حسب وصفة الطبيب تمامًا. يجب عليك التحقّق مع طبيبك أو مع الصيدلي إذا لم تكن متأكّدًا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة أخذ هذا الدواء</strong></p><p dir="RTL">إبلع القرص كاملاً مع الماء مع الطعام أو بدونه. يمكن أخذ القرص في أيّ وقت من النهار. ولكن حاول أخذ قرصك في الوقت نفسه كلّ يوم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الكميّة التي يجب أخذها</strong></p><p dir="RTL">&bull; تبلغ الجرعة الموصى بها 2 ملغرام مرّة واحدة في اليوم. بعد بضعة أسابيع قد يقرّر طبيبك زيادة جرعتك. تبلغ الجرعة القصوى للبالغين والأطفال فوق 10 سنوات 4 ملغرام كلّ يوم.&nbsp;</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل كبديّة لا يجدر بك أخذ أكثر من 2 ملغرام في اليوم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستعمال لدى الأطفال والمراهقين.</strong>&nbsp;</p><p dir="RTL">&bull; تبلغ الجرعة القصوى لدى الأطفال ما دون العشر سنوات 2 ملغرام كلّ يوم.&nbsp;</p><p dir="RTL">&bull; عند الضرورة، يمكن إذابة الأقراص في كوب ماء قبل أخذها تمامًا ومن ثمّ شطف الكوب مع حجم ثانٍ من الماء وشربه على الفور. لا تستعمل عصائر الفاكهة أو الحليب لإذابة الأقراص.&nbsp;</p><p dir="RTL">&bull; لا يوصى باستعمال ليفازو<strong><sup>م</sup></strong> لدى الأطفال ما دون السادسة من العمر. &nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أمور أخرى يجب عليك معرفتها&nbsp; في خلال فترة العلاج بليفازو</strong><strong><sup>م</sup></strong></p><p dir="RTL">&bull; إذا دخلت المستشفى أو تلقّيت علاجًا لمشكلة أخرى، أعلم الفريق الطبّي أنّك تأخذ ليفازو<strong><sup>م</sup></strong>.&nbsp;</p><p dir="RTL">&bull; قد يُجري لك طبيبك فحوصات منتظمة للكولسترول.&nbsp;</p><p dir="RTL">&bull; لا تتوقّف عن أخذ ليفازو بدون التحدّث إلى طبيبك أوّلاً. قد تزداد مستويات الكولسترول لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت كميّة من ليفازو</strong><strong><sup>م</sup></strong><strong> أكثر من التي عليك أخذها</strong></p><p dir="RTL">إذا أخذت كميّة من ليفازو<strong><sup>م</sup></strong> أكثر من التي عليك أخذها، تحدّث إلى الطبيب أو اذهب إلى المستشفى على الفور. خذ علبة الدواء معك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أخذ جرعة</strong></p><p dir="RTL">لا تقلق، خذ جرعتك التالية في الوقت الصحيح. لا تأخذ جرعة مضاعفة للتعويض عن الجرعة التي فوّتها.&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مثل الأدوية كلّها، يمكن أن يسبّب ليفازو<strong><sup>م</sup></strong> تأثيرات جانبيّة لا تُصيب المرضى كلّهم. يمكن حصول التأثيرات الجانبيّة التالية مع هذا الدواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL">توقّف عن أخذ ليفازو<strong><sup>م</sup></strong> وراجع الطبيب على الفور إذا لاحظت أيًّا من التأثيرات الجانبيّة الخطيرة التالية &ndash; قد تحتاج إلى علاج طبّي طارئ:</p><p dir="RTL">&bull; ارتكاس تحسسي &ndash; قد تتضمّن الإشارات: صعوبة في التنفّس، تورّم الوجه أو الشفتين أو اللسان أو الحلق، مشاكل في البلع، حكة حادة في الجلد (مع كتل مرتفعة).&nbsp;</p><p dir="RTL">&bull; ألم أو ضعف عضلي غير مبرّر، لا سيّما إذا كنت تشعر بتوعّك أو كانت حرارتك مرتفعة أو كان لون بولك أحمر مائلاً إلى البنّي. نادرًا ما يمكن أن يسبّب ليفازو<strong><sup>م</sup></strong> (أقلّ من شخص من أصل 1000 شخص) تأثيرات عضليّة مزعجة. في حال لم يتمّ التحقّق من هذه التأثيرات يمكنها أن تؤدّي إلى انهيار عضلي غير طبيعي (انحلال عضلي) مما يمكن أن يسبّب مشاكل كلويّة.&nbsp;</p><p dir="RTL">&bull; مشاكل في التنفّس تتضمّن سعالاً مستمرًّا و/أو ضيق نفس أو حمّى.</p><p dir="RTL">&bull; مشاكل في الكبد قد تسبّب اصفرار في البشرة والعينين (يرقان)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&bull; التهاب البنكرياس (ألم حاد في البطن والظهر)&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية الأخرى:</p><p dir="RTL">التأثيرات الشائعة (تصيب أقلّ من شخص من أصل 10 أشخاص)</p><p dir="RTL">&bull; ألم في المفاصل، وجع عضلي</p><p dir="RTL">&bull; إمساك، إسهال، عسر هضم، غثيان</p><p dir="RTL">&bull; صداع</p><p dir="RTL">&nbsp;</p><p dir="RTL">التأثيرات غير الشائعة (تصيب أقلّ من شخص من أصل 100 شخص)</p><p dir="RTL">&bull; تشنّجات عضليّة</p><p dir="RTL">&bull; شعور بالضعف أو بالإرهاق أو بالتوعّك</p><p dir="RTL">&bull; تورّم الكاحلين أو القدمين أو أصابع اليدين</p><p dir="RTL">&bull; ألم في المعدة، جفاف في الفم، غثيان، فقدان الشهيّة، تغيّر حاسة الذوق</p><p dir="RTL">&bull; شحوب البشرة والشعور بالضعف أو بضيق نفس (فقر دم)</p><p dir="RTL">&bull; حكاك أو طفح جلدي</p><p dir="RTL">&bull; طنين في الأذنين</p><p dir="RTL">&bull; شعور بدوار أو بنعاس، أرق (اضطرابات أخرى في النوم تتضمّن كوابيس)</p><p dir="RTL">&bull; زيادة الحاجة للتبوّل (تكرّر بولي)</p><p dir="RTL">&bull; شعور بالتنمل و ضعف الإحساس (نقص الحسّ) في أصابع اليدين والقدمين، في الساقين والوجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التأثيرات النادرة (تصيب أقلّ من شخص من أصل 1000 شخص)</p><p dir="RTL">&bull; مشاكل في الكبد</p><p dir="RTL">&bull; التهاب البنكرياس</p><p dir="RTL">&bull; احمرار البشرة، بشرة حمراء متورّمة تسبّب حكّة</p><p dir="RTL">&bull; تدهور في النظر</p><p dir="RTL">&bull; ألم في اللسان</p><p dir="RTL">&bull; شعور مزعج في البطن</p><p dir="RTL">&bull; تضخم الثدي عند الرجال (التثدي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">التأثيرات الجانبيّة غير المعروف معدّل حصولها</p><p dir="RTL">&bull; ضعف عضليّ ثابت</p><p dir="RTL">&bull; متلازمة شبيهة بالذئبة (بما في ذلك الطفح الجلدي واضطرابات المفاصل وتأثيراتها على خلايا الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأثيرات جانبيّة محتملة أخرى</p><p dir="RTL">&bull; فقدان الذاكرة</p><p dir="RTL">&bull; صعوبات جنسيّة</p><p dir="RTL">&bull; اكتئاب</p><p dir="RTL">&bull; داء السكري. تكون معرّضًا للإصابة بداء السكري إذا كان لديك مستويات مرتفعة من السكر والدهون في دمك وكان وزنك زائدًا وكنت تعاني من ارتفاع في ضغط الدم. قد يراقبك طبيبك في خلال فترة علاجك بهذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال أصبح أحد التأثيرات الجانبيّة مزعجًا أو إذا لاحظت أيّ تأثيرات جانبيّة غير مذكورة في هذه النشرة، الرجاء أن تُعلم الطبيب أو الصيدلي.</p><p dir="RTL">للإبلاغ عن أي آثار جانبية<br />لبنان وجميع دول الشرق الأوسط وشمال أفريقيا<br />القوريثم ش.م.ل<br />فاكس: +961-9-222141<br />البريد الإلكتروني: pharmacovigilance@algorithm-lb.com<br />موقع الكتروني: www.algorithm-lb.com<br />المملكة العربية السعودية<br />الاتصال أيضا:<br />المركز الوطني للتيقظ الدوائي (NPC):<br />فاكس: +966-11-205-7662<br />مركز اتصال الهيئة العامة للغذاء والدواء: 19999<br />البريد الإلكتروني: npc.drug@sfda.gov.sa<br />الموقع الإلكتروني: https://ade.sfda.gov.sa<br />اتصل أيضًا بالسلطة المختصة ذات الصلة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إحفظ الدواء بعيداً عن متناول الأطفال و نظرهم.</p><p dir="RTL">إحفظ الدواء في حرارة لا تتعدى 30 درجة مئويّة.&nbsp;</p><p dir="RTL">لحماية الدواء من النور أبقِ الظروف في علبة الكرتون.&nbsp;</p><p dir="RTL">لا تستعمل ليفازو بعد إنقضاء تاريخ الصلاحيّة المدوّن على علبة الكرتون والظرف بعد كلمة EXP. يشير تاريخ إنتهاء الصلاحيّة الى اليوم الأخير من الشهر المذكور. &nbsp;</p><p dir="RTL">لا ينبغي التخلّص من الأدوية عبر المياه المبتذلة أو مع النفايات المنزليّة. اسأل الطبيب أو الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعد بحاجة إليها، فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفاعلة هي بيتافاستاتين.</p><p dir="RTL">يحتوي كلّ قرص على 2.09 ملغرام أو 4.18 ملغرام من بيتافاستاتين الكلسيوم، مما يعادل 2 ملغرام أو 4 ملغرام بالتتابع من القاعدة الحرّة.&nbsp;</p><p dir="RTL">المكونات الأخرى هي: لاكتوز وحيد التميّه، هيدروكسيبروبيل سلولوز المنخفض التبديل، هبروميلوز (E464)، ألومينوميتاسيليكات المغنيزيوم، ستيارات المغنيزيوم، ثاني أكسيد التيتانيوم (E171)، سيترات ثلاثيّ الإيثيل (E1505) وسيليكا غروانيّة لا مائيّة. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف هو شكل ليفازو</strong><strong><sup>م</sup></strong><strong> ومحتويات العلبة</strong></p><p dir="RTL">أقراص ليفازو هي مستديرة، بيضاء، ثنائيّة التحدّب ومطليّة الغشاء محفور عليها &ldquo;ALG&rdquo; على جهة واحدة و&ldquo;L2&rdquo; أو &ldquo;L4&rdquo; على الجهة الأخرى.&nbsp;</p><p dir="RTL">يأتي ليفازو في علب من 7 أو 28 أو 30 أو 100 قرص.&nbsp;</p><p dir="RTL">قد لا تكون أحجام العلب كلّها مسوّقة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مالك رخصة التسويق والمصنع المسؤول عن تحرير الصنف:</p><p dir="RTL">ألغوريتم ش.م.ل. ذوق مصبح ، لبنان</p><p dir="RTL">&nbsp;</p><p dir="RTL">الشركة المصنّعة:</p><p dir="RTL">ألغوريتم ش.م.ل. ذوق مصبح ، لبنان</p><p dir="RTL">بإذن من كوا فارماسوتيكال أوروبا كو. ش.م.م.، المملكة المتّحدة.</p><p dir="RTL">&nbsp;<sup>م</sup> ماركة مسجلة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Livazo 2mg film-coated tablets.  
Livazo 4mg film-coated tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains pitavastatin calcium equivalent to 2mg & 4mg pitavastatin correspondingly.  
Excipient(s) include Lactose. For a full list of excipients see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.  
Round white film-coated tablets engraved ‘ALG’ on one side and ‘L2’ or ‘L4’on the other. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Livazo is indicated for the reduction of elevated total cholesterol (TC) and LDL-C, in adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures is inadequate.<strong>&nbsp; </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Patients should be on a cholesterol lowering diet before treatment. It is important that all patients continue dietary control during treatment.&nbsp;</p><p>The usual starting dose is 1 mg once daily. Adjustment of dose should be made at intervals of 4 weeks or more. Doses should be individualized according to LDL-C levels, the goal of therapy and patient response. The maximum daily dose is 4 mg.&nbsp;</p><p><u>Elderly</u></p><p>No dose adjustment necessary in patients older than 70 years (see <u>section 5.1</u> and <u>section 5.2</u>).&nbsp;</p><p><u>Paediatric population</u>&nbsp;</p><p>Children and adolescents aged 6 years and over:&nbsp;</p><p>Livazo use in children should only be carried out by physicians experienced in the treatment of hyperlipidaemia and progress should be regularly reviewed.&nbsp;</p><p>In children and adolescents with heterozygous familial hypercholesterolaemia the usual starting dose is 1 mg once daily. Adjustment of dose should be made at intervals of 4 weeks or more. Doses should be individualized according to LDL-C levels, the goal of therapy and patient response. In children 6 to 9 years of age the maximum daily dose is 2 mg. In children 10 years or older the maximum daily dose is 4 mg (see <u>sections 4.8, 5.1</u> and <u>5.2</u>).</p><p><em>Children younger than 6 years of age: </em></p><p>The safety and efficacy of Livazo in children below 6 years of age has not been established and no data are available.&nbsp;</p><p><u>Patients with impaired renal function</u></p><p>No dosage adjustment is required in mild renal impairment but pitavastatin should be used with caution. Data with 4 mg dose are limited in all grades of impaired renal function. Therefore 4 mg dose should ONLY be used with close monitoring after graded dose titration. In those with severe renal impairment 4 mg dose is not recommended (see <u>section 4.4</u> and <u>section 5.2</u>).&nbsp;</p><p><u>Patients with mild to moderate impaired hepatic function:</u>&nbsp;</p><p>The 4 mg dose is not recommended in patients with mild to moderate impaired hepatic function. A maximum daily dose of 2 mg may be given with close monitoring (see <u>section 4.4</u> and <u>section</u></p><p><u>5.2</u>).&nbsp;</p><p>&nbsp;</p><p><u>Method of Administration</u></p><p>For oral use only and should be swallowed whole. Livazo can be taken at any time of the day with or without food. It is desirable that the patient takes the tablet at the same time each day. Statin therapy is generally more effective in the evening due to the circadian rhythm of lipid metabolism.&nbsp;</p><p>If a child or adolescent is unable to swallow the tablet, where necessary, the tablet may be dispersed in a glass of water and taken immediately. To ensure accurate dosage a second volume of water should be used to rinse the glass and swallowed immediately. Tablets must not be dispersed in either acidic fruit juices or milk.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Livazo is contraindicated: 
•	in patients with known hypersensitivity to pitavastatin or to any of the excipients or other statins 
•	in patients with severe hepatic impairment, active liver disease or unexplained persistent elevations in serum transaminases (exceeding 3 times the upper limit of normal [ULN]) 
•	in patients with myopathy 
•	in patients receiving concomitant ciclosporin 
•	during pregnancy, while breast feeding and in women of child bearing potential not taking appropriate contraceptive precautions 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Muscle effects&nbsp;</p><p>In common with other HMG-CoA reductase inhibitors (statins), there is the potential for myalgia,<strong> </strong>myopathy and, rarely, rhabdomyolysis to develop. Patients should be asked to report any muscle symptoms. Creatine kinase (CK) levels should be measured in any patient reporting muscle pain, muscle tenderness or weakness especially if accompanied by malaise or fever.</p><p>&nbsp;</p><p>Creatine kinase should not be measured following strenuous exercise or in the presence of any other plausible cause of CK increase which may confound interpretation of the result. When elevated CK concentrations (&gt;5x ULN) are noted, a confirmatory test should be performed within 5 to 7 days.</p><p>&nbsp;</p><p>There have been very rare reports of an immune-mediated necrotizing myopathy (IMNM) during or after treatment with some statins. IMNM is clinically characterized by persistent proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.&nbsp;</p><p>&nbsp;</p><p>Livazo must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been report of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see <u>section 4.5</u>). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness.&nbsp;</p><p>&nbsp;</p><p>Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g., for the treatment of severe infections, the need for co-administration of Livazo and fusidic acid should only be considered on a case by case basis and under close medical supervision.&nbsp;&nbsp;</p><p>&nbsp;</p><p><u>Before Treatment</u></p><p>&nbsp;</p><p>In common with other statins, Livazo should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. A creatinine kinase level should be measured, to establish a reference baseline, in the following situations:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal impairment,&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypothyroidism,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; personal or family history of hereditary muscular disorders,&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; previous history of muscular toxicity with a fibrate or another statin,&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; history of liver disease or alcohol abuse,&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; elderly patients with other predisposing risk factors for rhabdomyolysis,&nbsp;</p><p>&nbsp;</p><p>In such situations, clinical monitoring is recommended and the risk of treatment should be considered in relation to the possible benefit. Treatment with Livazo should not be started if CK values are &gt;5x ULN.</p><p>&nbsp;</p><p><u>During Treatment</u></p><p>Patients must be encouraged to report muscle pain, weakness or cramps immediately. Creatine kinase levels should be measured and treatment stopped if CK levels are elevated (&gt;5x ULN).&nbsp; Stopping treatment should be considered if muscular symptoms are severe even if CK levels are</p><p>&le;5x&nbsp;</p><p>ULN. If symptoms resolve and CK levels return to normal, then re-introduction of Livazo may be considered at a dose of 1 mg and with close monitoring.</p><p>&nbsp;</p><p>Liver Effects</p><p>In common with other statins, Livazo should be used with caution in patients with a history of liver&nbsp; disease or who regularly consume excessive quantities of alcohol. Liver function tests should be performed prior to initiating treatment with Livazo and then periodically during treatment. Livazo treatment should be discontinued in patients who have a persistent increase in serum transaminases (ALT and AST) exceeding 3x ULN.</p><p>&nbsp;</p><p>Renal Effects</p><p>Livazo should be used with caution in patients with moderate or severe renal impairment. Dose increments should be instituted only with close monitoring. In those with severe renal impairment, 4 mg dose is not recommended (see <u>section 4.2</u>).</p><p>&nbsp;</p><p>Diabetes Mellitus</p><p>Some evidence suggests that statins as a class raise blood glucose and in some patients, at&nbsp; high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk of hyperglycaemia (fasting glucose 5.6 to 6.9 mmol/L, BMI&gt;30kg/m2, raised triglycerides, hypertension,) should be monitored both clinically and biochemically according to national guidelines. However, there has been no confirmed signal of a diabetes risk for pitavastatin either in post-marketing safety surveillance studies or in prospective studies (see <u>section 5.1</u>).&nbsp;</p><p>&nbsp;</p><p>Interstitial Lung Disease</p><p>Exceptional cases of interstitial lung disease have been reported with some statins, especially with long <strong>&nbsp;</strong>term therapy (see Section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>There is limited data on the long term effect on growth and sexual maturation in paediatric patients 6 years of age or older taking Livazo. adolescent females should be counselled on appropriate contraceptive precautions during treatment with Livazo (see <u>section 4.3, section 4.6</u>).&nbsp;</p><p>&nbsp;</p><p>Other effects</p><p>A temporary suspension of Livazo is recommended for the duration of treatment with erythromycin,&nbsp; other macrolide antibiotics or fusidic acid (see Section 4.5). Livazo should be used with caution in patients taking drugs known to cause myopathy (e.g. fibrates or niacin see Section 4.5).</p><p>&nbsp;</p><p>The tablets contain lactose. Patients with the rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pitavastatin is actively transported into human hepatocytes by multiple hepatic transporters (including organic anion transporting polypeptide, OATP), which may be involved in some of the following interactions.&nbsp;</p><p><strong>Ciclosporin: </strong>Co-administration of a single dose of ciclosporin with Livazo at steady state resulted in a 4.6-fold increase in pitavastatin AUC. The effect of steady state ciclosporin on steady state Livazo is not known. Livazo is contraindicated in patients being treated with ciclosporin (see <u>section 4.3</u>).<strong>&nbsp; </strong></p><p><strong>Erythromycin: </strong>Co-administration with Livazo resulted in a 2.8-fold increase in pitavastatin AUC. A temporary suspension of Livazo is recommended for the duration of treatment with erythromycin or other macrolide antibiotics.</p><p>&nbsp;</p><p><strong>Gemfibrozil and other fibrates:</strong> the use of fibrates alone is occasionally associated with myopathy. Co-administration of fibrates with statins has been associated with increased myopathy and rhabdomyolysis. Livazo should be administered with caution when used concomitantly with fibrates (see <u>section 4.4</u>). In Pharmacokinetic studies co-administration of Livazo with Gemfibrozil resulted in a 1.4 fold increase in pitavastatin AUC; with Fenofibrate AUC, increased 1.2-fold.&nbsp;</p><p>&nbsp;</p><p><strong>Niacin: </strong>Interaction studies with Livazo and niacin have not been conducted. The use of niacin alone has been associated with myopathy and rhabdomyolysis when used as a monotherapy. Thus Livazo should be administered with caution when used concomitantly with niacin.&nbsp;</p><p>&nbsp;</p><p><strong>Fusidic acid: </strong>The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination. If treatment with systemic fusidic acid is necessary, Livazo treatment should be discontinued throughout the duration of the fusidic acid treatment (see <u>section 4.4</u>).</p><p><strong>Rifampicin:</strong> Co-administration with Livazo at the same time resulted in a 1.3-fold increase in pitavastatin AUC due to reduced hepatic uptake.&nbsp;</p><p><strong>Protease inhibitors:</strong> Co-administration with Livazo at the same time may result in minor changes in pitavastatin AUC.&nbsp;</p><p><strong>Ezetimibe:</strong> and its glucuronide metabolite inhibit the absorption of dietary and biliary cholesterol. Co-administration of Livazo had no effect on plasma ezetimibe or the glucuronide metabolite concentrations and ezetimibe had no impact on pitavastatin plasma concentrations.&nbsp;</p><p><strong>Inhibitors of CYP3A4:</strong> Interaction studies with itraconazole and grapefruit juice, known inhibitors of CYP3A4, had no clinically significant effect on the plasma concentrations of pitavastatin.&nbsp;</p><p><strong>Digoxin</strong>, a known P-gp substrate, did not interact with Livazo. During co-administration there was no significant change in either pitavastatin or digoxin concentrations.&nbsp;</p><p><strong>Warfarin:</strong> The steady-state pharmacokinetics and pharmacodynamics (INR and PT) of warfarin in healthy volunteers was unaffected by the co-administration of Livazo 4 mg daily. However, as for other statins, patients receiving warfarin should have their prothrombin time or INR monitored when Livazo is added to their therapy.&nbsp;</p><p>Paediatric population&nbsp;</p><p>Drug-drug interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>Livazo is contraindicated during pregnancy (see Section 4.3). Women of childbearing potential must take appropriate contraceptive precautions during treatment with Livazo. Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk for inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies show evidence of reproductive toxicity, but no teratogenic potential (see <u>Section 5.3</u>). If the patient is planning to become pregnant, treatment should be stopped at least one month prior to conception. If a patient becomes pregnant during use of Livazo, treatment must be discontinued immediately.</p><p>Breastfeeding</p><p>Livazo is contraindicated during breastfeeding (see section 4.3). Pitavastatin is excreted in rat milk. It is not known whether it is excreted in human milk.&nbsp;</p><p>Fertility</p><p>No current data</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no pattern of adverse events that suggests that patients taking Livazo will have any impairment of ability to drive and use hazardous machinery, but it should be taken into account that there have been reports of dizziness and somnolence during treatment with Livazo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile &nbsp;</p><p>In controlled clinical trials, at the recommended doses, less than 4% of Livazo treated patients were withdrawn due to adverse events. The most commonly reported pitavastatin related adverse reaction in controlled clinical trials was myalgia.&nbsp;</p><p>Summary of adverse reactions &nbsp;</p><p>Adverse reactions and frequencies observed in worldwide controlled clinical trials and extension studies, at the recommended doses, are listed below by system organ class. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100, to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000) and not known.&nbsp;</p><p><u>Blood and the lymphatic system disorders</u>&nbsp;</p><p><em>Uncommon: </em>Anaemia</p><p><u>Metabolism and nutrition disorders</u>&nbsp;</p><p><em>Uncommon: </em>Anorexia</p><p>&nbsp;</p><p><u>Psychiatric disorders</u>&nbsp;</p><p><em>Uncommon: </em>Insomnia</p><p>Nervous system disorders&nbsp;</p><p><em>Common: </em>Headache&nbsp;</p><p><em>Uncommon: </em>Dizziness, Dysgeusia, Somnolence</p><p><u>Eye disorders</u>&nbsp;</p><p><em>Rare: </em>Visual acuity reduced</p><p><u>Ear and labyrinth disorders</u>&nbsp;</p><p><em>Uncommon: </em>Tinnitus</p><p>Gastrointestinal disorders&nbsp;</p><p><em>Common: </em>Constipation, Diarrhoea, Dyspepsia, Nausea&nbsp;</p><p><em>Uncommon: </em>Abdominal Pain, Dry Mouth, Vomiting <em>Rare: </em>Glossodynia, pancreatitis acute</p><p>Hepato-biliary disorders&nbsp;</p><p><em>Uncommon: </em>Transaminases (aspartate aminotransferase, alanine aminotransferase)increased&nbsp;</p><p><em>Rare: </em>Jaundice cholestatic</p><p>Skin and subcutaneous tissue disorders&nbsp;</p><p><em>Uncommon: </em>Pruritus, Rash&nbsp;</p><p><em>Rare: </em>Urticaria, Erythema</p><p>Musculoskeletal, connective tissue and bone disorders&nbsp;</p><p><em>Common: </em>Myalgia, Arthralgia&nbsp;</p><p><em>Uncommon: </em>Muscle spasms</p><p><em>Frequency unknown:</em> Immune-mediated necrotizing myopathy (see <u>section 4.4</u>)</p><p><u>Renal and urinary disorders</u>&nbsp;</p><p><em>Uncommon: </em>Pollakiuria</p><p>General disorders and administration site conditions&nbsp;</p><p><em>Uncommon: </em>Asthenia, Malaise, Fatigue, Peripheral Oedema</p><p>Elevated blood creatinine kinase of &gt;3 times the upper limit of normal (ULN) occurred in 49 out of 2800 (1.8%) patients receiving Livazo in the controlled clinical trials. Levels of &ge;10 times ULN with concurrent muscle symptoms were rare and only observed in one patient out of 2406 treated with 4mg Livazo (0.04%) in the clinical trial programme.</p><p>Paediatric population</p><p>The clinical safety database includes safety data for 142 paediatric patients who received pitavastatin among which 87 patients were in the age range of 12 to 17. In total, 91 patients received pitavastatin for 1 year with 12 patients receiving pitavastatin for 2.5 years and 2 patients for 3 years. Less than 3% pitavastatin treated patients were withdrawn due to adverse events. The most commonly reported pitavastatin related adverse reactions in the clinical programme were headache (4.9%), myalgia (2.1%) and abdominal pain (4.9%). Based on the data available, the frequency, type and severity of adverse reactions are expected to be similar in children and adolescents to adults.&nbsp;</p><p>Post Marketing Experience &nbsp;</p><p>A two year prospective post-marketing surveillance study was conducted in nearly 20,000 patients in Japan. The overwhelming majority of the 20,000 patients in the study were treated with 1 mg or 2 mg pitavastatin and not 4 mg. 10.4% of patients reported adverse events for which a causal relationship to pitavastatin could not be ruled out and 7.4% of patients withdrew from therapy due to adverse events. The myalgia rate was 1.08%. The majority of adverse events were mild. Adverse event rates were higher over 2 years in patients with a history of drug allergy (20.4%), or hepatic or renal disease (13.5%).&nbsp;</p><p>Adverse reactions and frequencies observed in the prospective post-marketing surveillance study but not in worldwide controlled clinical trials, at the recommended doses are listed below.</p><p><u>Hepato-biliary disorders</u>&nbsp;</p><p><em>Rare: </em>Hepatic function abnormal, Liver disorder</p><p>Musculoskeletal, connective tissue disorders&nbsp;</p><p><em>Rare: </em>Myopathy, Rhabdomyolysis</p><p>In the post-marketing surveillance study there were two reports of rhabdomyolysis requiring hospitalisation (0.01% of patients).</p><p>In addition there are unsolicited post-marketing reports of skeletal muscle effects including myalgia and myopathy in Livazo treated patients at all recommended doses. Reports of rhabdomyolysis, with and without acute renal failure are very rare including rhabdomyolysis fatal have also been received. Unsolicited reports of the following events have also been received (the frequency is based on that observed in postmarketing studies):</p><p>Nervous system disorders&nbsp;</p><p><em>Uncommon</em>: Hypoaesthesia</p><p>Gastrointestinal disorders&nbsp;</p><p><em>Rare</em>: Abdominal discomfort</p><p>Statin class effects</p><p>The following adverse events have been reported with some statins:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleep disturbances, including nightmares</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Memory loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual dysfunction</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes Mellitus: Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30kg/m2, raised triglycerides, history of hypertension)</p><p>&nbsp;</p><p><u>Reporting to National regulatory authority:</u></p><p><strong>To report any side effects: </strong></p><p>&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC):&nbsp;</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Ext: 2317-2356-2340</p><p>Reporting hotline: 19999&nbsp;</p><p>Email: npc.drug@sfda.gov.sa&nbsp;</p><p>Website: www. sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. The patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: HMG-CoA reductase inhibitors</p><p>ATC Code: C10A A08</p><p>&nbsp;</p><p>Mechanism of Action &nbsp;</p><p>Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver. As a result the expression of LDL receptors in the liver is increased, promoting the uptake of circulating LDL from the blood, decreasing total cholesterol (TC) and LDL-cholesterol (LDL-C) concentrations in the blood. Its sustained inhibition of hepatic cholesterol synthesis reduces VLDL secretion into the blood, reducing plasma triglyceride (TG) levels.</p><p>&nbsp;</p><p>Pharmacodynamic Effects &nbsp;</p><p>Livazo reduces elevated LDL-C, total cholesterol and triglycerides and increases HDLcholesterol&nbsp;</p><p>(HDL-C). It reduces Apo-B, and produces variable increases in Apo-A1 (see <u>Table 1</u>). It also reduces non-HDL-C and elevated TC/HDL-C, and Apo-B/Apo-A1 ratios.</p><p>&nbsp;</p><p>Table 1: Dose response in patients with primary hypercholesterolaemia (Adjusted mean percent change from baseline over 12 weeks) &nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:314px"><tbody><tr><td style="vertical-align:top"><p><strong>Dose </strong></p></td><td style="vertical-align:top"><p><strong>N </strong></p></td><td style="vertical-align:top"><p><strong>LD</strong></p><p><strong>L-C </strong></p></td><td style="vertical-align:top"><p><strong>TC</strong></p><p><strong>* </strong></p></td><td style="vertical-align:top"><p><strong>HD</strong></p><p><strong>L-C </strong></p></td><td style="vertical-align:top"><p><strong>TG </strong></p></td><td style="vertical-align:top"><p><strong>Apo</strong></p><p><strong>-B </strong></p></td><td style="vertical-align:top"><p><strong>Apo</strong></p><p><strong>-A1 </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Plac ebo </strong></p></td><td style="vertical-align:top"><p><strong>51 </strong></p></td><td style="vertical-align:top"><p><strong>-4.0 </strong></p></td><td style="vertical-align:top"><p><strong>-1.3 </strong></p></td><td style="vertical-align:top"><p><strong>2.5 </strong></p></td><td style="vertical-align:top"><p><strong>-2.1 </strong></p></td><td style="vertical-align:top"><p><strong>0.3 </strong></p></td><td style="vertical-align:top"><p><strong>3.2 </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>1mg </strong></p></td><td style="vertical-align:top"><p><strong>52 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>33.3 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>22.8 </strong></p></td><td style="vertical-align:top"><p><strong>9.4 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>14.8 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>24.1 </strong></p></td><td style="vertical-align:top"><p><strong>8.5 </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>2mg </strong></p></td><td style="vertical-align:top"><p><strong>49 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>38.2 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>26.1 </strong></p></td><td style="vertical-align:top"><p><strong>9.0 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>17.4 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>30.4 </strong></p></td><td style="vertical-align:top"><p><strong>5.6 </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>4mg </strong></p></td><td style="vertical-align:top"><p><strong>50 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>46.5 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>32.5 </strong></p></td><td style="vertical-align:top"><p><strong>8.3 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>21.2 </strong></p></td><td style="vertical-align:top"><p><strong>-</strong></p><p><strong>36.1 </strong></p></td><td style="vertical-align:top"><p><strong>4.7 </strong></p></td></tr></tbody></table><p>*unadjusted&nbsp;</p><p>&nbsp;</p><p>Clinical efficacy &nbsp;</p><p>In controlled clinical studies which enrolled a total of 1687 patients with primary hypercholesterolaemia and mixed dyslipidaemia, including 1239 patients treated at the therapeutic doses (mean baseline LDL-C about 4.8 mmol/L), Livazo consistently reduced LDLC, TC, non-HDL- C, TG and Apo-B concentrations and elevated HDL-C and Apo-A1 concentrations. TC/HDL-C and Apo-B/Apo-A1 ratios were reduced. LDL-C was reduced by 38 to 39% with Livazo 2mg and 44 to 45% with Livazo 4mg. The majority of patients taking 2mg achieved the European Atherosclerosis Society (EAS) treatment target for LDL-C (&lt;3 mmol/L).</p><p>In a controlled clinical trial in 942 patients aged &ge;65 years (434 treated with Livazo 1mg, 2mg or 4mg) with primary hypercholesterolaemia and mixed dyslipidaemia (mean baseline LDL-C about 4.2 mmol/L), LDL-C values were reduced by 31%, 39.0% and 44.3%, respectively, and about 90% of patients reached the EAS treatment target. More than 80% of the patients were taking concomitant medications, but the incidence of adverse events was similar in all treatment groups and fewer than 5% of patients withdrew from the study due to adverse events. Safety and efficacy findings were similar in patients in the different age subgroups (65-69, 70-74, and &ge;75 years).</p><p>&nbsp;</p><p>In controlled clinical trials which enrolled a total of 761 patients (507 treated with Livazo 4mg) who had primary hypercholesterolaemia or mixed dyslipidaemia, with 2 or more cardiovascular risk factors (mean baseline LDL-C about 4.1 mmol/L), or mixed dyslipidaemia with type 2 diabetes (mean baseline LDL-C about 3.6 mmol/L), approximately 80% achieved the relevant EAS target (either 3 or&nbsp;</p><p>2.5 mmol/L, depending on risk). LDL-C was reduced by 44% and 41%, respectively, in the patient groups.</p><p>&nbsp;</p><p>In long term studies of up to 60 weeks duration in primary hypercholesterolaemia and mixed dyslipidaemia, EAS target attainment has been maintained by persistent and stable reductions of LDL- C, and HDL-C concentrations have continued to increase. In a study in 1346 patients who had completed 12 weeks of statin therapy (LDL-C reduction 42.3%, EAS target attainment 69%, HDL-C elevation 5.6%), values after a further 52 weeks of treatment with pitavastatin 4mg were LDL-C reduction 42.9%, EAS target attainment 74%, HDL-C elevation 14.3%.</p><p>&nbsp;</p><p>In an extension to the two year surveillance study conducted in Japan (LIVES-01, see <u>section</u> <u>4.8</u>), 6582 patients with hypercholesterolaemia who had received treatment with pitavastatin 1, 2, or 4 mg for 2 years, were continued on treatment for a further 3 years (5 years total treatment). During this 5 year study, LDL-C reduction (-30.5%) was maintained from 3 months for the duration of the study, HDL-C values increased by 1.7% at 3 months to 5.7% at 5 years, with greater HDL-C increases seen in patients with lower baseline HDL-C values (&lt; 40 mg/dL), e.g. serum levels increased by 11.9% at 3 months to 28.9% after 5 years were observed.&nbsp;</p><p>&nbsp;</p><p>Atherosclerosis</p><p>The JAPAN-ACS study compared the effects of 8 to 12 month&rsquo;s treatment with pitavastatin 4 mg or atorvastatin 20 mg on coronary plaque volume in 251 patients undergoing percutaneous coronary intervention for Acute Coronary Syndrome, guided by intravascular ultrasound. This study demonstrated approximately 17% reduction in plaque volume for both treatments (-16.9 &plusmn; 13.9% with pitavastatin and -18.1 &plusmn; 14.2% with atorvastatin). Non-inferiority was proven between pitavastatin and atorvastatin and vice versa. In both cases, plaque regression was associated with negative vessel remodeling (113.0 to 105.4 mm&sup3;). There was no significant correlation between LDL-C reduction and plaque regression in this study, in contrast to the findings in placebo-controlled studies.&nbsp;</p><p>&nbsp;</p><p>The beneficial effects on mortality and morbidity have not yet been evaluated.</p><p>&nbsp;</p><p>Diabetes Mellitus</p><p>In an open-label prospective controlled study in 1269 Japanese patients with impaired glucose tolerance randomised to lifestyle modification with or without Livazo 1 mg or 2 mg daily, 45.7% of patients in the control group developed diabetes in comparison to 39.9% of patients in the Livazo group over a 2.8 year period, hazard ratio 0.82 [ 95% CI 0.68-0.99]. <strong>&nbsp;</strong></p><p>&nbsp;</p><p>A meta-analysis of 4815 non-diabetic patients included in randomised controlled double-blind studies of at least 12-weeks duration (weighted mean follow-up 17.3 weeks [ SD 17.7 weeks]) demonstrated a neutral effect for Livazo on the risk of new-onset diabetes (0.98% of control patients and 0.50% of Livazo patients developed diabetes, relative risk 0.70 [95% CI 0.30-1.61]) whilst 6.5% (103/1579) of control patients were treated with placebo; the rest were treated with statins including atorvastatin, pravastatin and simvastatin.&nbsp;</p><p>&nbsp;</p><p>Paediatric population&nbsp;</p><p>In a double-blind, randomized, multi-centre, placebo-controlled study NK-104-4.01EU (n=106; 48 male and 58 female) children and adolescent patients (&ge; 6 years of age and &lt; 17 years of age) with high-risk hyperlipidaemia (fasting plasma LDL-C levels &ge; 160 mg/dL (4.1 mmol/L), or LDL-C &ge; 130 mg/dL (3.4 mmol/L) with additional risk factors) received pitavastatin 1mg, 2mg, 4mg or placebo daily for 12 weeks. At study entry, the majority of the patients were diagnosed with heterozygous familial hypercholesterolaemia, approximately 41% of the patients were 6 to &lt;10 years old and approximately 20%, 9%, 12%, and 9% were Tanner stage II, III, IV, and V, respectively. Mean LDL-C was reduced 23.5%, 30.1%, and 39.3% by pitavastatin 1, 2 and 4 mg, respectively, compared to 1.0% for placebo.&nbsp;</p><p>&nbsp;</p><p>In a 52-week open-label extension and safety study NK-104-4.02EU (n=113, including 87 patients from the 12-week placebo-controlled study; 55 male and 58 female) children and adolescent patients (&ge; 6 years of age and &lt; 17 years of age) with high-risk hyperlipidaemia received pitavastatin for 52 weeks. All patients started treatment with pitavastatin 1mg daily, and the dose of pitavastatin may have been up-titrated to 2mg and 4 mg to achieve an optimum LDLC treatment target of &lt;110 mg/dL (2.8 mmol/L) based on LDL-C values at Week 4 and Week 8.</p><p>At study entry, approximately 37% of the patients were 6 to &lt;10 years old and approximately 22%, 11%, 12%, and 13% were Tanner stage II, III, IV, and V, respectively. The majority of patients (n=103) were up-titrated to 4 mg pitavastatin daily. Mean LDL-C was reduced 37.8% at the week 52 endpoint. In total, 47 patients (42.0%) achieved the AHA minimal LDL-C target of &lt; 130 mg/dL and 23 patients (20.5%) achieved the AHA ideal LDL-C target of &lt; 110 mg/dL at week 52. The reduction in mean LDL-C at the week 52 endpoint was 40.2% for patients &ge; 6 to &lt; 10 years of age (n=42), 36.7% for patients &ge; 10 to &lt; 16 years of age (n=61), and 34.5% for patients &ge; 16 to &lt; 17 years of age (n=9). Patient gender did not appear to have an effect on response. In addition mean TC was decreased 29.5% and mean TG was decreased 7.6% at the week 52 endpoint.&nbsp;</p><p>&nbsp;</p><p>The European Medicines Agency Paediatric Committee has waived the obligation to submit the results of studies in children under the age of 6 years and in the treatment of children of all ages with homozygous familial hypercholesterolaemia.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption: </strong>Pitavastatin is rapidly absorbed from the upper gastrointestinal tract and peak plasma concentrations are achieved within one hour after oral administration. Absorption is not affected by food. Unchanged drug undergoes enterohepatic circulation and is well absorbed from the jejunum and ileum. The absolute bioavailability of pitavastatin is 51%.<strong> </strong></p><p>&nbsp;</p><p><strong>Distribution: </strong>Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 133 L. Pitavastatin is actively transported into hepatocytes, the site of action and metabolism, by multiple hepatic transporters including OATP1B1 and OATP1B3. Plasma AUC is variable with an approximately 4-fold range between the highest and lowest values. Studies with SLCO1B1 (the gene which encodes OATP1B1) suggests that polymorphism of this gene could account for much of the variability in AUC. Pitavastatin is not a substrate for p-glycoprotein.&nbsp;</p><p>&nbsp;</p><p><strong>Biotransformation: </strong>Unchanged pitavastatin is the predominant drug moiety in plasma. The principal metabolite is the inactive lactone which is formed via an ester-type pitavastatin glucuronide conjugate by UDP glucuronosyltransferase (UGT1A3 and 2B7). In vitro studies, using 13 human cytochrome P450 (CYP) isoforms, indicate that the metabolism of pitavastatin by CYP is minimal; CYP2C9 (and to a lesser extent CYP2C8) is responsible for the metabolism of pitavastatin to minor metabolites.</p><p>&nbsp;</p><p><strong>Elimination: </strong>Unchanged pitavastatin is rapidly cleared from the liver in the bile, but undergoes enterohepatic recirculation, contributing to its duration of action. Less than 5% of pitavastatin is excreted in the urine. The plasma elimination half-life ranges from 5.7 hours (single dose) to 8.9 hours (steady state) and the apparent geometric mean clearance is 43.4 L/h after single dose.</p><p>&nbsp;</p><p><strong>Effect of food: </strong>The maximum plasma concentration of pitavastatin was reduced by 43% when it was taken with a high-fat meal, but AUC was unchanged.</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p><strong>Elderly: </strong>In a pharmacokinetic study which compared healthy young and elderly (&ge;65 years) volunteers, pitavastatin AUC was 1.3-fold higher in elderly subjects. This has no effect on the safety or efficacy of Livazo in elderly patients in clinical trials.</p><p>&nbsp;</p><p><strong>Gender: </strong>In a pharmacokinetic study which compared healthy male and female volunteers, pitavastatin AUC was increased 1.6-fold in women. This has no effect on the safety or efficacy of Livazo in women in clinical trials.</p><p>&nbsp;</p><p><strong>Race: </strong>There was no difference in the pharmacokinetic profile of pitavastatin between Japanese and Caucasian healthy volunteers when age and body weight was taken into account.</p><p>&nbsp;</p><p><strong>Paediatric population:</strong> There are limited pharmacokinetic data in children and adolescents. In study NK-104-4.01EU (see <u>section 5.1</u>) sparse sampling revealed a dose-dependent effect on pitavastatin plasma concentrations at 1 hour post dose. There was also indication that concentration at 1 hour post dose were (inversely) related to body weight and may be higher in children than adults.&nbsp;</p><p><strong>Renal insufficiency: </strong>For patients with moderate renal disease and those on haemodialysis increases in AUC values were 1.8-fold and 1.7-fold respectively (see <u>section 4.2</u>).&nbsp;</p><p>&nbsp;</p><p><strong>Hepatic insufficiency: </strong>For patients with mild (Child-Pugh A) hepatic impairment AUC was 1.6 times that in healthy subjects, while for patients with moderate (Child-Pugh B) hepatic impairment AUC was 3.9-fold higher. Dose restrictions are recommended in patients with mild and moderate hepatic impairment (see <u>section 4.2</u>). Livazo is contraindicated in patients with severe hepatic impairment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on results from conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Indications of renal toxicity were seen in monkeys at exposures greater than those reached in adult humans administered the maximum daily dose of 4mg and urinary excretion plays a far greater role in the monkey than in other animal species. In vitro studies with liver microsomes indicate that a monkey- specific metabolite may be implicated. The renal effects observed in monkeys are unlikely to have clinical relevance for humans, however the potential for renal adverse reactions cannot be completely excluded.</p><p>Pitavastatin had no effect on fertility or reproductive performance and there was no evidence of teratogenic potential. However, maternal toxicity was observed at high doses. A study in rats indicated maternal mortality at or near term accompanied by foetal and neonatal deaths at doses of 1 mg/kg/day (at least 12.5 fold greater than the highest dose in humans on a mg/kg bodyweight basis). No studies have been conducted in juvenile animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core&nbsp;</p><p>Lactose monohydrate&nbsp;</p><p>Low substituted hydroxypropylcellulose Hypromellose (E464)&nbsp;</p><p>Magnesium Aluminometasilicate&nbsp;</p><p>Magnesium stearate&nbsp;</p><p>Film coating&nbsp;</p><p>Hypromellose (E464)&nbsp;</p><p>Titanium dioxide (E171)</p><p>&nbsp;Triethyl citrate (E1505)&nbsp;</p><p>Colloidal anhydrous silica</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>in the original package.&nbsp;</p><p>Protect from light. Do not store above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White PVdC coated PVC/AL blisters in cartons of 7, 28, 30 or 100 tablets.&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>To protect the environment, do not dispose of via waste water or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Algorithm SAL, Lebanon 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2017 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>